A trial of bleomycin versus adriamycin in advanced carcinoma of the bladder.
Thirty-seven patients were studied in a controlled clinical trial to assess the value of Adriamycin and Bleomycin in the treatment of advanced carcinoma of the bladder. The previously reported high response rates for both drugs were not observed in this trial. Administration of Bleomycin was accompanied by a toxicity rate so high that treatment had to be abandoned. Neither Adriamycin nor Bleomycin, therefore, used as single agents, have a role in the chemotherapy of advanced bladder cancer. Other agents should be investigated and assessed by controlled clinical trials that are disease-orientated rather than drug-orientated.
D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D001761:Bleomycin; D004317:Doxorubicin